# Lecture 19: Genetic Testing, Gene Editing, and the Ethics of Enhancement
## Foundations of Medical Ethics and the Health Humanities
---
## Learning Objectives
By the end of this lecture, students will be able to:
1. Describe the types and purposes of genetic testing and their ethical implications
2. Analyze the ethical debates surrounding germline vs. somatic gene editing
3. Distinguish between therapy and enhancement and evaluate the ethical significance of this distinction
4. Discuss the implications of CRISPR and related technologies for individuals, families, and society
5. Evaluate justice concerns related to genetic technologies, including access and eugenics
---
## Lecture Content
### I. Genetic Testing: Types and Applications
Genetic testing encompasses a wide range of techniques, each with distinct purposes. Diagnostic testing confirms or rules out a genetic condition in a symptomatic individual. Predictive or presymptomatic testing identifies genetic risk in asymptomatic individuals, as with BRCA1/2 testing for breast and ovarian cancer risk or testing for Huntington's disease. Carrier testing identifies individuals who carry one copy of a recessive gene, such as sickle cell trait or cystic fibrosis carrier status. Prenatal testing screens for genetic conditions in the fetus through amniocentesis, chorionic villus sampling, or cell-free fetal DNA analysis. Newborn screening involves mandatory screening for treatable conditions such as phenylketonuria and hypothyroidism. Pharmacogenomic testing predicts drug response based on genetic profile. Direct-to-consumer (DTC) testing, offered commercially by companies like 23andMe, provides information about ancestry, health predispositions, and carrier status.
Several ethical issues cut across all forms of genetic testing. Informed consent is particularly challenging because genetic information is complex and ensuring genuine understanding requires considerable effort. The right not to know must be respected: some individuals may prefer not to learn about genetic risks, especially for untreatable conditions like Huntington's disease. Privacy and discrimination are serious concerns, as genetic information can be used by insurers, employers, or others to discriminate. GINA (the Genetic Information Nondiscrimination Act of 2008) prohibits discrimination in health insurance and employment based on genetic information in the United States, but it does not cover life, disability, or long-term care insurance. Genetic information about one person inherently reveals information about relatives who did not consent to testing, creating tension between the patient's confidentiality and the potential benefit to family members (as discussed in Lecture 6). The psychological impact of genetic testing -- including anxiety, guilt, altered self-concept, and effects on family relationships -- can be profound. And incidental findings, unexpected results unrelated to the original purpose of testing, present their own disclosure dilemmas.
### II. Prenatal and Preimplantation Genetic Testing
Non-invasive prenatal testing (NIPT) uses cell-free fetal DNA from maternal blood to screen for trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and sex chromosome anomalies. Diagnostic procedures such as amniocentesis and chorionic villus sampling provide definitive results but carry a small risk of miscarriage.
Prenatal testing raises profound ethical debates. If testing reveals a genetic condition, parents face the decision of whether to continue the pregnancy. Approximately 67% of pregnancies with a prenatal diagnosis of Down syndrome are terminated in the United States, with higher rates in some European countries. The disability rights critique argues that routine screening and selective termination send a message that lives with disability are not worth living and constitute a form of de facto eugenics. The autonomy argument responds that parents have the right to make informed reproductive decisions. Non-directive counseling is the standard of practice, with genetic counselors presenting information neutrally without steering the decision, though in practice the framing of information inevitably carries implicit messages. Sex selection is permitted in some contexts, such as for sex-linked genetic diseases, but is ethically contested when used for family balancing or cultural preference.
Preimplantation genetic testing (PGT) in the context of IVF (covered in Lecture 9) includes PGT-M for monogenic disorders such as cystic fibrosis and sickle cell disease, and PGT-A for aneuploidy (chromosomal abnormalities). The practice of creating "savior siblings" -- selecting an embryo that is a compatible tissue donor for an existing sick child -- is ethically complex, balancing the instrumentalization of the child against the possibility of saving a life.
A decision tree for prenatal genetic testing. Start: "Prenatal screening offered." Branch 1: "Screening positive (high risk)." Sub-branch: "Offer diagnostic testing (amniocentesis/CVS)." If confirmed: "Genetic counseling: discuss condition, prognosis, available supports, options." Options: "Continue pregnancy with support and planning," "Selective termination," "Adoption planning." Branch 2: "Screening negative (low risk)." Sub-branch: "Routine prenatal care; acknowledge residual uncertainty." At each decision point, ethical considerations are noted: autonomy, non-directive counseling, disability rights perspective, psychological impact.
### III. Gene Editing: CRISPR and Beyond
CRISPR-Cas9 is a revolutionary gene-editing tool that allows precise modification of DNA sequences. It is cheaper, faster, and more accurate than previous methods such as zinc finger nucleases and TALENs. Its applications span basic science, disease modeling, drug development, and therapeutic gene editing.
Somatic gene editing targets non-reproductive cells, meaning changes are not inherited by future generations. Examples include editing T cells to fight cancer (CAR-T therapy) and correcting genetic defects in affected tissues, as in emerging treatments for sickle cell disease and beta-thalassemia. The ethical status of somatic gene editing is generally accepted, as it is analogous to other medical treatments and governed by standard clinical trial ethics. Challenges include off-target effects, delivery methods, long-term safety, cost, and equitable access.
Germline gene editing targets reproductive cells (sperm, eggs) or early embryos, meaning changes are heritable and passed to all future descendants. It has the potential to eliminate heritable genetic diseases permanently. While technically possible, it is not clinically approved in any jurisdiction. The He Jiankui case of 2018, in which a Chinese scientist created the first gene-edited babies (twin girls with edits to the CCR5 gene intended to confer HIV resistance), was universally condemned for lack of informed consent, unclear medical necessity, unknown long-term risks, and premature application of unproven technology. He was sentenced to prison, and the case catalyzed global calls for governance frameworks.
Arguments against germline editing emphasize safety concerns (off-target effects could introduce new diseases with unknown multigenerational consequences), consent issues (future generations cannot consent to heritable modifications), justice considerations (the technology would likely be available only to the wealthy, exacerbating inequality), the risk of opening the door to enhancement, concerns about "playing God" or hubris in redesigning the human genome, and disability rights perspectives (editing out genetic conditions implies they are defects to be eliminated).
Arguments for germline editing, contingent on established safety, note that it could prevent devastating genetic diseases in entire family lines, that parents already make genetic choices through partner selection and prenatal screening and germline editing is a more precise version of these choices, and that refusing to use available technology to prevent suffering may itself be unethical.
### IV. The Therapy-Enhancement Distinction
Therapy involves restoring normal function or treating disease, such as correcting sickle cell disease. Enhancement involves improving capabilities beyond the normal range, such as increasing intelligence, athletic ability, or altering physical appearance. This distinction matters ethically because most people accept therapy as appropriate while enhancement raises deeper concerns about fairness, authenticity, and the meaning of human achievement.
However, the distinction is difficult to maintain in practice. The definition of "normal" is culturally and historically contingent -- conditions like short stature, ADHD, and aging occupy contested territory between disease and normal variation. Many current medical interventions are enhancement-like: cosmetic surgery, Adderall for cognitive performance, and growth hormone for short stature without deficiency all blur the therapy-enhancement line.
Specific enhancement concerns include cognitive enhancement through drugs like modafinil and methylphenidate or through gene editing for intelligence, which raises fairness questions in education and employment. Physical enhancement through gene doping threatens the integrity of athletics. Cosmetic genetics -- selecting embryos for height, eye color, or skin color -- reinforces social hierarchies and commodifies children. Life extension through genetic modifications to slow aging would have profound implications for resource allocation and social inequality.
A spectrum diagram from left to right. Left: "Clear Therapy" (examples: correcting sickle cell disease, treating cystic fibrosis, restoring hearing with cochlear implants). Middle: "Gray Zone" (examples: growth hormone for short stature without deficiency, LASIK for normal vision, cosmetic surgery, cognitive enhancers for typical cognition). Right: "Clear Enhancement" (examples: editing for superior intelligence, selecting embryos for height or eye color, gene doping for athletic performance, radical life extension). Below the spectrum: "The line between therapy and enhancement is not fixed -- it shifts with cultural norms, technology, and definitions of health."
### V. Justice and Genetic Technologies
Access and inequality represent critical justice concerns. Genetic technologies are expensive and concentrated in wealthy countries and institutions. If germline editing or genetic enhancement becomes available, it could create a "genetic underclass" -- a division between those who can afford modifications and those who cannot, reminiscent of the scenario depicted in the film Gattaca.
The relationship between genetic technologies and eugenics demands careful attention. Historical eugenics involved state-sponsored programs to improve the gene pool through forced sterilization, immigration restrictions, and marriage laws. "New eugenics" describes individual reproductive choices enabled by technology -- prenatal screening, PGT, germline editing -- that may produce eugenic outcomes without state coercion. The line between individual reproductive autonomy and societal eugenic effects remains deeply contested.
Governance of genetic technologies is evolving. International bodies such as the WHO Expert Advisory Committee on Human Genome Editing and National Academies of Sciences reports provide guidance, but no binding international treaty on germline editing exists. Calls for a moratorium or global governance framework continue. Above all, inclusive public deliberation is essential: these decisions affect all of humanity and should not be made by scientists alone.
---